Superb Crew interviewed Asymmetrex Director James Sherley to discuss the latest Asymmetrex report of a new advance on stem cell immortality. This interview goes into detail about how stem cell immortality is connected with kinetic stem cell counting, how it will impact the future of kinetic stem cell counting technology, and Asymmetrex’s connection to this
Asymmetrex has partnered with Proventa International to provide an online workshop on kinetic tissue stem cell counting for better medicine through counting stem cells to improve regenerative and pharmaceutical medicines. The online workshop is on February 18, 2021 at 11AM PST / 2PM EST. In 2020, the FDA’s Standards Coordinating Body (SCB) identified specific counting
On September 30, stem cell biotechnology company Asymmetrex presented at the 2020 Outsourcing in Clinical Trials USA Virtual Conference. In addition to discussing the value of tissue stem cell counting for better practices in stem cell and gene therapy clinical trials, Asymmetrex director James Sherley also highlighted value that stem cell counting technologies can impart
In a recent report published in the journal OBM Transplantation, stem cell biotechnology company Asymmetrex reported the first counts of therapeutic “true” tissue stem cells in the history of stem cell science and medicine. This crucial research and clinical data, long-needed for accelerating the development of new and better stem cell medicines, is now readily
In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the
Today, June 16, Massachusetts stem cell biotechnology company Asymmetrex announces that it will begin offering free tissue stem cell counting on its company website. Scheduled for opening July 5, Independence Day weekend in the U.S., the company’s counting site will give academic scientists, stem cell medicine physicians, tissue stem cell suppliers, and drug companies a
May 12, 2020 In Arena International’s Clinical Trial Supply 2020 Virtual Experience online conference, Asymmetrex Director James Sherley discussed unique challenges in the supply chain of therapies for stem cell transplantation medicine, gene therapy, and gene-editing therapy that can be readily addressed by greater use of tissue stem cell counting technologies like those developed
Today, at the 6th Annual Perinatal Stem Cell Society Congress in Salt Lake City, Utah, Massachusetts stem cell biotechnology company Asymmetrex will announce its newest advance in technologies for specific counting of tissue stem cells. The company will report the use of its AlphaSTEM Test™ technology to discover the first mathematical algorithms for rapidly calculating
On October 2, 2019, the United Kingdom Intellectual Property Office issued a patent to Massachusetts stem cell biotechnology company Asymmetrex. The patent covers the company’s invention of the first and only technology for counting tissue stem cells specifically and identifying agents that affect tissue stem cells, positively or negatively. The new patent is another advance